Arterial stiffness and emerging biomarkers: Still a long journey to go

Angiology

Volumn 66, Issue 10, 2015, Pages 901-903

  Doumas, Michael ^a,b   Papademetriou, Vasilios ^c   Athyros, Vasilios ^b   Karagiannis, Asterios ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; URIC ACID;

ARTERIAL STIFFNESS; AUGMENTATION INDEX; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; EDITORIAL; HEART HEMODYNAMICS; HUMAN; LIPID ACCUMULATION PRODUCT INDEX; LIPOPROTEIN METABOLISM; META ANALYSIS (TOPIC); NONHUMAN; PULSE PRESSURE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CARDIOVASCULAR DISEASES; FEMALE; HEMODYNAMICS; INDEPENDENT LIVING; MALE;

ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; FEMALE; HEMODYNAMICS; HOMOCYSTEINE; HUMANS; INDEPENDENT LIVING; MALE; TRIGLYCERIDES; VASCULAR STIFFNESS;

EID: 84943542801     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319715594291     Document Type: Editorial

References (30)

1. GBD 2013 mortality and causes of death collaboration. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385 (9963): 117-171.
2. Kannel WB, Dawber TR, Revotskie N, Stokes J III,. Factors of risk in the development of coronary heart disease: six year follow-up experience. The Framingham study. Ann Intern Med. 1961; 55: 33-50.
3. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015; 131 (4): e29-e322.
4. Hackam DG, Anand SS,. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 2003; 290 (7): 932-940.
5. Hlatky MA, Greenland P, Arnett DK, et al. American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of CV risk: a scientific statement from the American Heart Association. Circulation. 2009; 119 (17): 2408-2416.
6. Vlachopoulos C, Aznaouridis K, Stefanadis C,. Aortic stiffness for cardiovascular risk prediction: just measure it, just do it. J Am Coll Cardiol. 2014; 63 (7): 647-649.
7. Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014; 63 (7): 636-646.
8. Papademetriou V, Katsiki N, Doumas M, Faselis C,. Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy. Curr Pharm Des. 2014; 20 (40): 6339-6349.
9. Fu S, Luo L, Ye P, Xiao W,. Multi-marker analysis for new biomarkers in relation to central arterial stiffness and hemodynamics in a Chinese community-dwelling population. Angiology. 2015. doi: 10.1177/0003319715573910.
10. Katsiki N, Koumaras C, Athyros VG, Karagiannis A,. Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology. 2012; 63 (1): 9-11.
11. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP,. Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors. Curr Med Res Opin. 2015; 31 (3): 435-438.
12. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP,. High density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality? Curr Med Chem. 2014; 21 (25): 2917-2926.
13. Kothapali D, Liu SL, Bae YH, et al. Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening. Cell Reports. 2012; 2 (5): 1259-1271.
14. Van den Bogaard B, Holleboom AG, Duivenvoorden R, et al. Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness. Atherosclerosis. 2012; 225 (2): 481-485.
15. Shimizu Y, Nakazato M, Sekita T, et al. Association of arterial stiffness and diabetes with triglycerides-to-HDL cholesterol ratio for Japanese men: the Nagasaki Islands Study. Atherosclerosis. 2013; 228 (2): 491-495.
16. Urbina EM, Khoury PR, McCoy CE, Dolan LM, Daniels SR, Kimball TR,. Triglyceride to HDL-C ratio and increased arterial stiffness in children, adolescents, and young adults. Pediatrics. 2013; 131 (4): e1082-e1090.
17. Hongo M, Tsutsui H, Mawatari E, et al. Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia. A 5-year follow-up study. Circ J. 2008; 72 (5): 722-728.
18. Wang G, He L, Liu J, et al. Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia. Cardiovasc Ther. 2013; 31 (3): 161-167.
19. Ryan KE, McCance DR, Powell L, McMahon R, Trimble ER,. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis. 2007; 194 (2): e123-e130.
20. Hiukka A, Westerbacka J, Leinonen ES, et al. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol. 2008; 52 (25): 2190-2197.
21. Sanders TA, Hall WL, Maniou Z, Lewis F, Seed PT, Chowienczyk PJ,. Effect of low doses of long-chain n-3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. Am J Clin Nutr. 2011; 94 (4): 973-980.
22. Pase MP, Grima NA, Sarris J,. Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomised controlled trials. Br J Nutr. 2011; 106 (7): 974-980.
23. Levy D, Hwang SJ, Kayalar A, et al. Associations of plasma natriuretic peptide, adrenomedullin, and homocysteine levels with alterations in arterial stiffness: the Framingham Heart Study. Circulation. 2007; 115 (24): 3079-3085.
24. Lieb W, Larson MG, Benjamin EJ, et al. Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study. Circulation. 2009; 119 (1): 37-43.
25. Vermeulen EGJ, Niessen HMW, Bogels M, Stehouwer CDA, Rauwerda JA, van Hinsbergh VWM,. Decreased smooth muscle cell/extracellular matrix ratio of media of femoral artery in patients with atherosclerosis and hyperhomocysteinemia. Arterioscler Thromb Vasc Biol. 2001; 21: 573-577.
26. Durga J, Bots ML, Schouten EG, et al. Effect of 3 y of folic acid supplementation on the progression of carotid intima-media thickness and carotid arterial stiffness in older adults. Am J Clin Nutr. 2011; 93 (5): 941-949.
27. Athyros VG, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP,. Effect of tobacco smoking and smoking cessation on plasma lipoproteins, and associated major cardiovascular risk factors: a narrative review. Curr Med Res Opin. 2013; 29 (10): 1263-1274.
28. Koumaras C, Tzimou M, Stavrinou E, et al. Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics. Am J Cardiovasc Drugs. 2012; 12 (3): 143-56.
29. Koumaras C, Tziomalos K, Stavrinou E, et al. Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens. 2014; 8 (2): 74-82.
30. Doumas M, Gkaliagkousi E, Katsiki N, et al. The effect of antihypertensive drugs on arterial stiffness and central hemodynamics: not all fingers are made the same. Open Hypertens J. 2013; 5 (suppl 1): 75-81.